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Comparison of limited surgery and 3D conformal radiation in high 
risk patients with Stage IA non small cell lung cancer (NSCLC): A 
propensity score matched analysis
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Introduction: Anatomic resection with lymph node sampling or 
systematic lymph node dissection is currently the standard of care for 
good performance patients with stage I NSCLC. Some patients with 
stage I NSCLC are unable to tolerate lobectomy because of limited 
lung function or prohibitive co-morbidities. Comparison of radiation 
therapy and limited surgical resection, the most commonly employed 
treatment modalities for these patients, is confounded by differences in 
co-morbidities in both patient populations. In this study we compared 
the outcome of patients treated with wedge resection or 3D conformal 
radiation therapy after controlling for these factors.
Methods: All patients with stage IA non small cell lung cancer from 
1988-2005 who were not considered candidates for anatomic surgi-
cal resection were reviewed. Univariate and multivariate analyses 
were performed to assess the inﬂuence of 3D conformal radiation and 
surgery on overall survival (OS), recurrence free survival (RFS) and 
disease speciﬁc survival (DSS). Propensity score matched analysis 
and cost assessments were performed to compare outcomes with both 
modalities. Propensity matching was performed for gender, histology, 
tumor size, performance status and age.
Results: Of a total of 151 patients included, 60 patients received 
limited resection and 91 patients received 3D conformal radiation. 
Univariate and multivariate analyses (Table 1) suggested a trend 
toward improved outcome in limited resection. In an effort to balance 
differences in co-morbidities in both groups, propensity matching was 
performed with 32 matched pairs and demonstrated no statistically 
signiﬁcant difference in OS, RFS or DSS (Table 2). The mean cost of 
radiation therapy ($32,735) was not statistically signiﬁcantly different 
from surgery ($30,411).
Conclusion: In high risk patients with NSCLC, limited resection has a 
tendency towards improved outcome. As propensity matched analysis 
did not show a clear beneﬁt for limited resection, this may be due in 
part to increased co-morbidities of patients treated with 3D conformal 
radiation.
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Background: Differentiating synchronous primary non-small cell lung 
cancers (SPLC) from more advanced disease remains challenging. By 
stage, patients with SPLC have a worse prognosis than those with a 
single primary but superior to what would be expected for stage IV 
disease. This study was conducted to elucidate the factors which affect 
survival in patients with presumed SPLC.
Methods: A retrospective review of a single institution prospective sur-
gical database identiﬁed patients treated for SPLC from January 1995 
through December 2005. Patients with carcinoid tumor were excluded. 
Demographic information, tumor characteristics, stage, treatment and 
survival data were analyzed. A complete pathological review by a 
single pathologist was performed on all available tumors. Survival was 
calculated from the date of the ﬁrst surgery, and either a log-rank test or 
Cox proportional hazards model was used to test for association with 
categorical and continuous variables, respectively.
Results: One hundred ninety-eight patients who underwent complete 
surgical resection of SPLC were identiﬁed. After excluding patients 
with carcinoid tumors (14), there was complete data on 175 patients. 
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Twenty-six percent (50/175) of these patients had more than 2 tumors. 
Greatest tumor size, female sex, T-, N-, M- and overall stage were all 
signiﬁcant predictors of survival (p <0.05). Compared with patients 
with similar histologies (n=146) those with different histologies (n=29) 
had greater 3-year survival (72 months [95%CI: 62-80] versus 47 
months [95%CI: 25-67], respectively). Neither tumor location (ipsi-
lateral vs. contralateral), the time of SPLC diagnosis (preoperatively 
versus intra- or postoperatively), or smoking history had an impact 
on survival. Median overall survival was 74 months (95%CI: 60-not 
estimable), with a 3-year overall survival of 67 % (95%CI: 58-75). 
Evaluating by the highest pathological stage lesion, patients with 
SPLC tumors had comparable 3-year survival rates to those expected 
in patients with similar stage single primary cancers (Graph). Twenty-
seven patients who had same lobe disease had a 3-year survival of 77% 
(95%CI: 53-90).
Conclusions: Identiﬁcation of SPLC by clinical and pathologic criteria 
coupled with aggressive treatment can lead to results that approach 
those seen with similar stage single primary disease. In particular, pa-
tients with synchronous disease in the same lobe, who otherwise would 
have been considered T4, have better than predicted survival.
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Prophylactic cranial irradiation (PCI) versus no PCI in extensive 
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Background: The phase III EORTC trial 22993-08993 demon-
strated that PCI signiﬁcantly reduces the risk of brain metastases 
(BM) (40.4% vs 14.6% at 1 yr) and prolongs survival (27.1% vs 
13.3% at 1 yr) in patients with ED- SCLC (ASCO 2007). Preventing 
BM will without any doubt prevent deterioration of QoL. However, the 
effects of PCI in cases who did not develop BM are uncertain. We now 
report the QoL results in that study.
Methods: Patients (18-75 years; ≤WHO2) with conﬁrmed ED-SCLC 
and showing response to induction chemotherapy, were randomized 
to PCI (doses ranging from 20 Gy/5 fr to 30 Gy/12 fr) or no PCI. QoL 
data (QLQ-C30 and BN20) were collected at baseline (i.e. at randomi-
sation within 5 weeks after last chemotherapy), 6 weeks, 3, 6, 9 and 12 
months and then every six months until 3 years or death. The primary 
QoL endpoints were global health status, hair loss, fatigue, role, cogni-
tive and emotional functioning. QoL scales range from 0-100: for 
function higher values represent better function, for symptoms higher 
values indicate greater symptom burden. Clinical signiﬁcance is a 10-
point difference, statistical signiﬁcance is P<0.01
Results: Between October 2001-March 2006, 286 patients entered the 
trial. Baseline characteristics were well balanced. Compliance to QoL 
was 93.7% (268/286) at baseline, 60.0% (162/270) at 6 weeks, 54.4% 
(128/235) at 3, 60.8% (79/130) at 6, and 46.3% (38/82) at 9 months 
and was not signiﬁcantly different between the two groups. The median 
survival (measured from time of randomization) was 6 months. The 
data from baseline to month 9 showed no statistically or clinically 
signiﬁcant difference in global health status (p=0.10). Main side effects 
of PCI were signiﬁcant hair loss and fatigue (see table), but no impact 
on role (p=0.17), cognitive (p=0.07) or emotional functioning (p=0.18) 
was observed. Exploratory analyses of the QoL scales showed statisti-
cally signiﬁcant and (near) clinically relevant differences for appetite 
loss, nausea/vomiting and weakness of legs in the ﬁrst months after 
PCI (see table). 
HE QoL score
Assessment 
time
PCI  
Score (SD)
Control 
Score (SD)
Treatment 
diﬀerence 
p-value
Hair loss 6 weeks 36.5 (3.96) 11.7 (3.73) <0.001
Fatigue 6 weeks 43.2 (2.56) 29.3 (2.47) <0.001
Fatigue 3 months 53.6 (3.03) 38.5 (3.24) <0.001
Appetite loss 6 weeks 28.9 (3.25) 10.6 (3.06) <0.001
Appetite loss 3 months 43.9 (3.87) 14.8 (4.18) <0.001
Nausea/vomiting 6 weeks 15.0 (1.73) 5.3 (1.64) <0.001
Nausea/vomiting 3 months 26.9 (2.92) 8.2 (3.15) <0.001
Weakness of legs 6 weeks 25.2 (2.71) 11.8 (2.48) <0.001
Weakness of legs 3 months 32.2 (3.62) 16.0 (3.93) 0.0026
 
Conclusions: Despite signiﬁcant early side effects of PCI, global health 
status was not signiﬁcantly inﬂuenced till far beyond the expected 
median survival of these patients. Patients with ED SCLC who respond 
to chemotherapy should routinely be offered PCI. 
This study was performed by the EORTC Radiation Oncology and 
Lung Cancer Groups.
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Initial results from an intergroup phase III trial evaluating two 
different doses of prophylactic cranial irradiation (PCI) in patients 
with limited small cell cancer (SCLC) in complete remission 
(PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212)
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